Acquiring Company
Jazz Pharmaceuticals plc
Acquired Company
Actio Biosciences
Dublin
San DiegoManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareTherapeuticsDescription
Jazz Pharmaceuticals has announced its acquisition of Actio Biosciences for $820 million upfront, with additional contingent payments of up to $500 million. This strategic move enhances Jazz's rare epilepsy portfolio, particularly focusing on the clinical asset ABS-1230 for KCNT1+ epilepsy. The acquisition emphasizes Jazz's commitment to addressing significant patient needs in the epilepsy community.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Actio Biosciences?
Actio Biosciences was acquired by Jazz Pharmaceuticals plc, based in Dublin. The deal was reported on August 10, 2026. Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options. Jazz Pharmaceuticals plc is publicly traded (JAZZ) and operates in Manufacturing.
When did Jazz Pharmaceuticals plc acquire Actio Biosciences?
Jazz Pharmaceuticals plc's acquisition of Actio Biosciences was reported on August 10, 2026. Jazz Pharmaceuticals has announced its acquisition of Actio Biosciences for $820 million upfront, with additional contingent payments of up to $500 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Actio Biosciences do?
Actio Biosciences is a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases. It is privately held, operating in Biotechnology, and is based in San Diego.